June 9, 2022 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D. A new report conducted by the actuarial firm Milliman, “A Summary of Insulin Coverage in Medicare Part D,” shows that insulin products are widely covered on Medicare Part D formularies. “We support
March 24, 2022 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and treatment at pharmacies and calling on the Biden Administration to expand the scope of its recently-announced “Test to Treat” program: “We applaud the Biden administration on its efforts to increase
March 16, 2022 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee for holding this important hearing on drug price inflation. We share the committee’s goal
January 6, 2022 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the 2023 Medicare Part D proposed rule from the Centers for Medicare & Medicaid Services (CMS): “We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare
November 3, 2021 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) Ppresident and CEO JC Scott issued the following statement on Congress’ agreement on drug pricing language for the budget bill: “We appreciate congressional negotiators’ focus on prescription drug prices and applaud inclusion of repeal of the rebate rule, a rule which threatens to dramatically increase premiums for Medicare
August 3, 2021 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the proposed amendment by Senator Mike Braun (R, Ind.) in the Bipartisan Infrastructure Framework (BIF) legislation: “The Senate’s inclusion of a provision to delay the Medicare rebate rule in the infrastructure legislation is a good start to full
May 19, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA), Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott, Virtual PBM Policy Forum 2021
Leading Headlines, Pharmacy
WASHINGTON — Today, the Pharmaceutical Care Management Association (PCMA) announced the Virtual PBM Policy Forum 2021, featuring health care, pharmacy benefit managers (PBMs), and pharmaceutical manufacturer industry thought leaders and executives discussing how the public and private sectors are tackling drug costs and improving the affordability and quality of care for patients. “We are pleased
May 18, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA), Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers use “patent thickets” to block generic or biosimilar competition from entering the market. For Humira, Enbrel,
May 12, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA), Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is announcing a new three-part policy platform, supported by America’s pharmacy benefit managers, PBMs, aimed at reducing prescription drug costs by updating Medicare Part D, enhancing competition, and building toward a more value-driven health care system for patients. “PCMA’s multi-faceted policy platform provides specific policy actions to
April 22, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA), Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott, Pharmaceutical Care Management Association president and CEO JC Scott
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the pending confirmations of three officials of the U.S. Department of Health and Human Services (HHS): Chiquita Brooks-LaSure, nominee for Administrator for the Centers for Medicare & Medicaid Services; Andrea Palm, nominee for Deputy Secretary; Melanie Egorin, nominee
March 29, 2021 by Chain Drug Review
Lee Ann Stember president and chief executive officer at the National Council for Prescription Drug Programs, Pharmaceutical Care Management Association, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — The number of independent pharmacies in the United States increased in 2020, according to a new analysis of pharmacy data. Pharmacy data from the National Council for Prescription Drug Programs, analyzed by the healthcare analytics firm Quest Analytics, shows the overall number of independent pharmacy stores increased by 449 between January 2020 and
March 1, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott, The Pharmaceutical Care Management Association (PCMA)
Leading Headlines, Pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal. “We applaud the Biden Administration for delaying the rebate rule’s effective date in order to further examine the rule’s impact on Medicare beneficiaries,” said
January 25, 2021 by Chain Drug Review
PCMA, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — A new report, “Pharmacy Services Administrative Organizations (PSAOs) and their Little-Known Connection to Independent Pharmacies,” sheds light on the role of PSAOs in the prescription drug supply and payment chain. The white paper, researched and written by the health care policy consulting firm Health Evaluations and released by the Pharmaceutical Care Management Association
January 14, 2021 by Chain Drug Review
Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott, The Pharmaceutical Care Management Association (PCMA)
Leading Headlines, Pharmacy
WASHINGTON – The Pharmaceutical Care Management Association (PCMA) released the following statement on the Senate Finance Committee’s report on insulin pricing: “We appreciate the Senate Finance Committee’s focus on insulin pricing and share their urgency in addressing affordability and access for insulin-dependent patients. While we are reviewing the committee’s findings, it’s important to understand that